Researchers at King’s College London have unveiled a groundbreaking strategy to fight Alzheimer’s disease by simultaneously addressing key early biological changes linked to the condition. Their study reveals that KCL-286, an experimental drug originally developed for spinal cord injuries and already successful in Phase 1 safety testing, effectively mitigates several symptoms of Alzheimer’s in mouse models.
“KCL-286 is a first-in-class, orally bioavailable small molecule that has already demonstrated safety and tolerability in humans during Phase 1 testing. This advancement could significantly shorten the typical multi-year timelines for new drug development,” stated Professor Jonathan Corcoran, a neuroscientist at the Institute of Psychiatry, Psychology and Neuroscience at King’s College London.
Exploring Beyond Amyloid and Tau
Alzheimer’s disease arises from a complex interplay of biological changes, with the most notable being the accumulation of amyloid beta and tau proteins, which lead to brain cell deterioration. Most current treatments primarily target amyloid beta, yielding only limited clinical benefits.
Researchers are now investigating additional biological processes that may contribute to Alzheimer’s earlier in its progression, including DNA damage and inflammation. These mechanisms could offer fresh avenues to slow the disease’s advancement.
In their recent study, KCL-286 was shown to repair damaged DNA and diminish inflammation in mouse models of Alzheimer’s disease. By addressing multiple pathogenic mechanisms simultaneously, this drug may provide a more comprehensive therapeutic strategy compared to existing treatments focused solely on amyloid or tau.
“Our results indicate that KCL-286 not only targets DNA damage but also alleviates inflammation, two crucial factors that manifest very early in Alzheimer’s progression. This highlights the potential of KCL-286 as a disease-modifying therapy, moving beyond mere symptom management,” remarked Dr. Maria Goncalves, who oversees the drug development project.
Mechanism of Action for KCL-286
KCL-286 functions by activating specific proteins within the retinoic acid pathway, essential for metabolizing vitamin A. Prior studies indicated that disruption of this pathway correlates with amyloid beta accumulation in rat models akin to Alzheimer’s disease.
The drug has demonstrated efficacy in repairing DNA double-strand breaks in research related to neuropathic pain. Based on these observations, researchers hypothesized that similar DNA damage in Alzheimer’s could also be amenable to repair.
“Double-strand breaks in DNA resemble ropes that are not just frayed but completely severed. Our findings show that KCL-286 facilitates the repair of these breaks, enabling us to target critical hallmarks of Alzheimer’s disease,” explained Professor Corcoran.
A Drug with Broader Potential
Previous investigations by the same King’s College London team identified a shared molecular pathway that connects acute spinal cord injury and Alzheimer’s disease, suggesting that KCL-286 could mitigate neurodegenerative changes associated with Alzheimer’s.
Natasha Hill, one of the study’s lead authors, emphasized: “Creating effective treatments for Alzheimer’s necessitates a multifaceted approach. KCL-286 targets several disease-related cellular pathways, some activated very early in the disease’s trajectory.”
Although these findings rely on mouse models, KCL-286’s successful completion of Phase 1 safety testing for another application could expedite future clinical developments as researchers explore its potential impact on Alzheimer’s patients.
Source: www.sciencedaily.com